Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-α in chemotherapy of multidrug-resistant hepatocellular carcinoma

Liver International

Volumn 30, Issue 4, 2010, Pages 585-592

  Li, Gaopeng ^a,b   Dong, Shengli ^c   Qu, Junyuan ^d   Sun, Zhengang ^a   Huang, Zhiyong ^a   Ye, Lu ^b   Liang, Huifang ^b   Ai, Xi ^b   Zhang, Wanguang ^b   Chen, Xiaoping ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SHANXI MEDICAL UNIVERSITY   (China)

^d Shanxi Tumour Hospital   (China)

Author keywords

Hepatocellular carcinoma; Multidrug resistance; Nanoparticle; Tumour necrosis factor

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLINE; DOXORUBICIN; FLUOROURACIL; HYDROXYAPATITE; KI 67 ANTIGEN; MESSENGER RNA; MITOMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; RECOMBINANT MUTANT TUMOR NECROSIS FACTOR ALPHA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INHIBITION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DURAPATITE; FEMALE; GENES, MDR; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS, EXPERIMENTAL; PROBABILITY; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950606551     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02113.x     Document Type: Article

References (48)

1. Okuda K. Hepatocellular carcinoma. J Hepatol 2000, 32:225-37.
2. Boucher E, Forner A, Reig M, Bruix J. New drugs for the treatment of hepatocellular carcinoma. Liver Int 2009, 29((Suppl. 1)):148-58.
3. Doyle LA, Yang W, Abruzzo LV. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95:15665-70.
4. Kowalski P, Stein U, Scheffer GL, Lage H. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther 2002, 9:579-86.
5. Uchino J, Une Y, Kawata A, Wakisaka Y, Hosokawa M. Postoperative chemoimmunotherapy for the treatment of liver cancer. Semin Surg Oncol 1993, 9:332-6.
6. Fukushima T, Yamamoto M, Ikeda K. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res 1998, 18:3965-70.
7. Nakamoto T, Inagawa H, Takagi K, Soma G. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res 2000, 20:4087-96.
8. Rosenberg SA, Lotze MT, Muul LM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985, 313:1485-92.
9. Tomita A, Fuchino Y, Otsuka K. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res 1998, 18:3937-9.
10. Lee KY, Chang W, Qiu D, Kao PN, Rosen GD. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 1999, 274:13451-5.
11. Hill AD, Redmond HP, Croke DT, Grace PA, Bouchier-Hayes D. Cytokines in tumour therapy. Br J Surg 1992, 79:990-7.
12. Lasek W, Giermasz A, Kuc K. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer 1996, 66:374-9.
13. Libutti SK, Barlett DL, Fraker DL, Alexander HR. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg 2000, 191:519-30.
14. Chcialowski A, Targowski T, Bajera I, Jahnz-Rozyk K. Tumor necrosis factor-alpha - phase I and phase II clinical trials. Pol Merkur Lekarski 1997, 2:396-9.
15. Du Bois JS, Trehu EG, Mier JW. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997, 15:1052-62.
16. Dong W, Zhou R, Zhou S. Experimental studies on antitumor activity of new recombinant human tumour necrosis factor in nude mice bearing nasopharyngeal carcinoma. Zhonghua Er Bi Yan Hou Ke Za Zhi 1998, 33:38-41.
17. Kim DW, Andres ML, Li J. Liposome-encapsulated tumor necrosis factor-alpha enhances the effects of radiation against human colon tumor xenografts. J Interferon Cytokine Res 2001, 21:885-97.
18. Azria D, Dorvillius M, Gourgou S. Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody. Int J Radiat Oncol Biol Phys 2003, 55:1363-73.
19. Jin Y, Tao X, Gao Y, Xiong X, Bai M. Influence of rmhTNF on the chemotherapy treatment of small cell lung cancer. J Huazhong Univ Sci Technol Med Sci 2006, 26:40-2.
20. Li G, Chen X, Wang Q. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J Huazhong Univ Sci Technol Med Sci 2007, 27:173-5.
21. Han Y, Li S, Wang X, Bauer I, Yin M. Sonochemical preparation of hydroxyapatite nanoparticles stabilized by glycosaminoglycans. Ultrason Sonochem 2007, 14:286-90.
22. Bauer IW, Li SP, Han YC, Yuan L, Yin MZ. Internalization of hydroxyapatite nanoparticles in liver cancer cells. J Mater Sci Mater Med 2008, 19:1091-5.
23. Gridley DS, Archambeau JO, Andres MA. Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts. Oncol Res 1997, 9:217-27.
24. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-21.
25. Li F, Ambrosini G, Chu EY. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-4.
26. Shiozaki EN, Chai J, Rigotti DJ. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003, 11:519-27.
27. Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 1996, 88:1383-92.
28. Ohno S, Strebel FR, Stephens LC. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats. Cancer Res 1992, 52:4096-101.
29. Uggla B, Stahl E, Wagsater D. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 2005, 29:141-6.
30. Abbott BL, Colapietro AM, Barnes Y. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002, 100:4594-601.
31. Lee JS, Scala S, Matsumoto Y. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem 1997, 65:513-26.
32. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 1987, 77:142-4.
33. Chen CJ, Chin JE, Ueda K. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-9.
34. van der Kolk DM, Vellenga E, Scheffer GL. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 2002, 99:3763-70.
35. Rybarova S, Hodorova I, Hajdukova M. Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters. Neoplasma 2006, 53:128-35.
36. Tahara H, Kusuhara H, Fuse E, Sugiyama Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 2005, 33:963-8.
37. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 2004, 64:3296-301.
38. Albermann N, Schmitz-Winnenthal FH, Z'graggen K. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005, 70:949-58.
39. Bellomo G, Perotti M, Taddei F. Tumor necrosis factor alpha induces apoptosis in mammary adenocarcinoma cells by an increase in intranuclear free Ca2+ concentration and DNA fragmentation. Cancer Res 1992, 52:1342-6.
40. Baumann S, Fas SC, Giaisi M. Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca2+-dependent apoptosis. Blood 2008, 111:2354-63.
41. Sawhney N, Hall PA. Ki67 - structure, function, and new antibodies. J Pathol 1992, 168:161-2.
42. Gramantieri L, Trere D, Chieco P. In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. J Hepatol 2003, 39:997-1003.
43. Nishiguchi I, Willingham V, Milas L. Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors. Int J Radiat Oncol Biol Phys 1990, 18:555-8.
44. Munoz-Martinez F, Lu P, Cortes-Selva F. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Cancer Res 2004, 64:7130-8.
45. Zhou XF, Yang X, Wang Q, Coburn RA, Morris ME. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab Dispos 2005, 33:1220-8.
46. Walter RB, Pirga JL, Cronk MR. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood 2005, 106:3584-93.
47. Zhang S, Yang X, Coburn RA, Morris ME. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 2005, 70:627-39.
48. Chang CC, Liang YC, Klutz A. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemother Pharmacol 2006, 58:640-53.